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Factor VIII is a  requisite molecule in the intrinsic pathway of blood coagulation 
and is functionally deficient in hemophilia A. Factor VIII coagulant activity (VIIIc) 
and Factor VIII-like antigen, or von Willebrand's disease  antigen (vW-Ag), appear 
to  be  biologically linked. They show  a  direct  quantitative relationship in normal 
individuals, both are decreased to a comparable degree  in most individuals with von 
Willebrand's disease,  and they are  isolated together under a  variety of  conditions 
(1-4). These observations have suggested that the molecule expressing vW-Ag may 
indeed be the same molecule that possesses VIIIc, namely the Factor VIII molecule. 
This unitary hypothesis, invoked to explain the observed biologic  linkage, has been 
brought into question by the observation of a marked disparity between VIIIc and 
vW-Ag in plasma of patients with von Willebrand's disease  after infusion of plasma 
or Factor VIII concentrates (5, 6). 
In this report we provide direct evidence that VIIIc and vW-Ag do not re- 
side on the identical molecule in plasma. We here demonstrate that antibodies, 
covalently coupled to  agarose  beads,  are capable of  binding and segregating 
these two entities one from the other. These data are consistent with a  two- 
molecule hypothesis in which VIIIc resides on the Factor VIII molecule and 
vW-Ag resides on a  biologically linked but different molecule, tentatively re- 
ferred to as the vW molecule.  1 
Materials and Methods 
Factor VIII Preparations.--Partially purified Factor  VIII containing  both VIIIc and 
vW-Ag was isolated by subjecting Factor VIII concentrates  (American National Red Cross 
Blood Research Laboratory,  Bethesda,  Md.) to molecular sieve chromatography on 5 X  45 
cm columns of Bio-Gel A-15 M, 200-400 mesh (Bio-Rad Laboratories, Richmond, Calif.), and 
collecting the void volume as described previously (1). 
Antisera.--Antiserum against Factor VIII preparations  was prepared  in New Zealand 
White rabbits (1). A polyvalent antiserum was constituted  by pooling multiple bleedings of 
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four animals, each with demonstrable antibody to vW-Ag by Ouchterlony analysis (1) and to 
VIIIc by neutralization assay  (2 Oxford units)  (8).  The pool was absorbed with 0.1  vol of 
supernatant plasma from a 3% cryoethanol precipitate (1) and with 0.02 vol of a pool of sera 
from patients with IgM myeloma proteins. The absorbed antisera formed a  single precipitin 
line in Ouchterlony gel double diffusion with crude cryoethanol concentrates, and exhibited 
identity with the precipitin line formed by the originally described antiserum to Factor VIII- 
like antigen  (vW-Ag)  (1). The gamma globulin fraction was isolated by ammonium sulfate 
fractionation and coupled to Sepharose 2B (agarose)  beads with cyanogen bromide (9). Gamma 
globulin concentration varied from 3 to 4  mg/ml beads with various lots, and these are re- 
ferred to as rabbit antibody beads. Rabbit control beads, possessing  comparable amounts of 
protein, were prepared with gamma globulin of unimmunized rabbits. 
The gamma globulin fraction of a  human anti-Factor VIII (with an VIIIc neutralizing 
potency of 235 Oxford units [8]), obtained from an individual with hemophilia A, was prepared 
and  comparable quantities of protein were coupled to Sepharose beads and are referred to as 
human antibody beads. Human control beads were prepared with normal human gamma glob- 
ulin. 
Coagulant Factor and vW-A g Assays.--Factor VIII and Factor IX coagulant activities were 
assayed by partial thromboplastin  time assays employing genetically deficient plasma sub- 
strates  (10). vW-Ag was assayed by quantitative immunoelectrophoresis as described previ- 
ously (1); however, the sensitivity of the latter assay was increased so as to permit assay of 
as little as 1.5% of the antigen concentration in normal plasma. This was accomplished by 
reduction of anti-vW antiserum concentration in the agarose gel, the use of 20-#1 sample vol, 
and staining of washed and fixed slides. ~ A pool of plasma from 20 normal healthy individuals, 
anticoagulated with citrate and stored frozen at --70°C, was used as the standard plasma. 
Immunochemical  Segregation of Molecules.--The capacity of antibody beads  to bind and 
remove VIII  c  and/or vW-Ag from the fluid phase was assayed by incubating varying vol- 
umes of antibody beads (from 25 to 400/zl) with 500/zl of pooled plasma. The beads were in- 
cubated with the plasma by rocking at 37°C for 4 h  and then sedimented by centrifugation 
at 5000 g for 5 min. The supernatant plasma was assayed for residual VIII  c  and vW-Ag. In 
all cases supernatant  plasma,  similarly incubated with control beads,  showed no significant 
loss of VIIIc or vW-Ag when corrected for dilution. Control supernatant plasma was used as 
the standard for assessing specific immunologic removal of VIIIc and vW-Ag, and the results 
are expressed relative to this control. 
RESULTS  AND  DISCUSSION 
Solid-phase antibodies provide a means of segregating molecules bearing anti- 
genic markers. Rabbit antibody beads, prepared from antiserum exhibiting both 
the  capacity  to neutralize VIIIc  and precipitate  vW-Ag,  do bind  and  remove 
both VIIIc and vW-Ag as illustrated in Fig. 1. The binding and removal of each 
is proportional  to the quantity of antibody beads.  However, the relative quan- 
tity  of  each  remaining  in  the  plasma  differs  after  incubation  with  antibody 
beads,  a  finding  inconsistent  with  a  unitary  hypothesis.  Such  an  hypothesis 
would require  that  the ratio of VIIIc  to vW-Ag remain constant.  After expo- 
sure to dilute rabbit antibody beads,  the VIIIc/vW-Ag  ratio increases from 1.0 
of the initial plasma to  1.47, and it progressively increases with increasing con- 
centration  of antibody  beads.  These observations indicate  differential  binding 
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FIG. 1. Immunologic  binding and removal from plasma of Factor VIII coagulant activity 
(VIIIc, O--C))  and von Willebrand's disease antigen (vW-Ag, Q--O) by solid-phase rab- 
bit antibodies. Rabbit gamma globulin exhibiting both anti-VIII  c and anti-vW-Ag  properties 
was coupled to agarose beads. Various amounts of antibody beads were incubated with normal 
human plasma. After centrifugation the supernatant plasmas were assayed for residual VlIIc 
and for vW-Ag. (Results are expressed relative to control supernatants from plasmas that had 
been incubated with similar quantities of rabbit control beads. Control beads had no effect 
beyond that of dilution.) The brackets include the mean and 1 SD for n = 4. Consistently less 
vW-Ag than VIIIc remained in the plasma. The ratio of residual VIIIc to vW-Ag (A  .....  A) 
increased as increasing quantities of both were removed by the antibody beads 
and partial  segregation of vW-Ag from VIIIc, a  finding inconsistent with  a 
unitary hypothesis. A unitary hypothesis would require that VIIIc and vW-Ag 
be bound to an equal degree. 
Direct evidence that rabbit antibody beads removed VIIIc from the standard 
plasma by immunologic binding was obtained in the following manner.  After 
incubation of rabbit antibody beads with plasma they were washed and assayed 
for resident VIIIc. 31 times more VIIIc was found on these beads as compared 
with rabbit control beads similarly exposed to plasma. In order to evaluate the 
specificity of the beads for VIIIc they were also assayed for Factor IX coag- 
ulant activity. No significant increase in Factor IX activity could be detected 
on the  antibody beads as compared with the control beads (ratio of 1.2:1). 
The effect of human antibody beads on plasma is  also inconsistent with  a 
unitary hypothesis. The results of 13 experiments illustrated in Fig. 2 demon- 
strate  binding  and  removal  of  58%  of VIIIc from  normal  human  plasma; 
whereas, no significant removal of vW-Ag was observed. The VIIIc to vW-Ag 
ratio,  1.0 in the initial  plasma exposed to human control beads, decreased to 
0.42 after exposure to the insolubilized human anti-VIIIc antibody. 
These studies provide direct evidence that VIIIc and vW-Ag can be physi- 
cally segregated by heterologous as  well  as homologous antibodies,  and  thus 
they cannot uniformly reside  on one and  the  same molecule in plasma.  The 
presence of vW-Ag cannot be considered as evidence, per se, for an inactive form 
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FIG. 2. Removal of Factor VIII coagulant activity (VIIIc) from plasma, independent of 
yon Willebrand's disease antigen (vW-Ag), by insolubilized human isoantibodies to VIIIc. 
Human antibodies to VIIIc were coupled  to agarose beads, incubated with normal human 
plasma, and removed  by centrifugation.  The supernatant plasma was assayed for residual 
VIII  c and vW-Ag and results are expressed as in Fig. 1 except that human control beads were 
used. 
blocking the  Factor VIII-neutralizing capacity of rabbit antibodies has  been 
found in the great majority of either hemophiliac plasmas (10)  or cryoethanol 
concentrates (1) or cryoprecipitates  3 from hemophiliac plasmas. This antigenic 
material would appear to represent inactive Factor VIII. In addition, a  solid- 
phase immunologic assay for Factor VIIP also detects antigenic material in the 
plasma of hemophiliacs. 
Recently, an additional factor with biologic linkage to the vW-Ag has been 
described  (11-15).  This  factor,  designated the  yon  Willebrand's Factor  (see 
Glossary of Definition of Terms), confers glass bead adhesiveness and ristocetin 
aggregability to human platelets. Like the vW-Ag, it is present in hemophilia 
but  often decreased in  von  Willebrand's disease. As is  the case with VIIIc, 
vW-Ag and the von Willebrand's disease factor are isolated together under  a 
variety of conditions. These considerations suggest that the molecule expressing 
vW-Ag may also possess von Willebrand's Factor activity. However, attractive 
as it may appear, this hypothesis remains to be proven. 
GLOSSARY OF DEFINITION  OF  TERMS 
Factor VIII Coagulant  (Antihemophilic Factor,  VllIc).--An  activity that corrects the co- 
agulation abnormality of hemophilic blood or plasma. Measured by coagulation assays. Prob- 
3 Fienstein, D. I., S. I. Rapaport, and M. M. Y. Chong. The differing effects of the 2 sub- 
types of hemophilia A(A  + and A-) upon the neutralizing activity of a rabbit antiserum  to 
human Factor VIII. Manuscript in preparation. 
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ably resides on a molecule distinct from that expressing the von Willebrand's  antigen, though 
both are biologically linked. Decreased in both classic hemophilia and yon Willebrand's dis- 
ease. 
The van Willebrand's Factor.--An activity that  confers ristocetin aggregability and  glass 
bad adhesivenes~ to human platelets. Shows a close biologic correlation with the molecule 
, xpressing the von WUlebrand's antigen though residence on the same molecule has not been 
established at present. Often decreased in von Willebrand's disease but normal in classic he- 
mophilia. 
The van Willebrand's Antigen (Factor VIII-Like Antigen, vW-A g).--A precipitating antigen 
that is often decreased in yon Willebrand's disease. Usually normal in classic hemophilia. 
The relationship of the Factor VIII molecule to the molecule bearing vW-Ag 
is not resolved. The nature of the biological linkage is open to a number of hy- 
pothetical speculations including the possibility that  the two  molecules exist 
in plasma as a  reversible complex; the vW molecule may be the precursor of 
Factor VIII; or the vW molecule may govern synthesis or release of Factor 
VIII from tissue sites. Elucidation of the biologic linkage of these two molecules 
should provide a  sound molecular approach to the pathobiology of those dis- 
eases associated with decreased or abnormal function of Factor VIII. 
SUMMARY 
Factor VIII coagulant activity (VIIIc) and the yon Willebrand's disease an- 
tigen (Factor VIII-like antigen, vW-Ag) are biologically linked, and it has been 
suggested that they reside on the same molecule. However, insolubilized human 
isoantibody to VIIIc and rabbit antiserum containing antibodies to VIIIc and 
vW-Ag differentially bind and remove these entities from plasma, thus physi- 
cally segregating one from the other. These findings indicate that Factor VIII 
coagulant activity resides on a  molecule distinct from that expressing the yon 
Willebrand's antigen. 
We are particularly indebted to the efforts of Miss Lynne de la Pointe without whose help 
this work could not have bzen completed. 
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